IO Biotech expects Phase 3 PFS readout in Q3 2025; cash of $60M extends runway to Q2 2026

IO Biotech, Inc.

Phase 3 trial (advanced melanoma) PFS primary endpoint readout delayed to Q3 2025; BLA submission still planned by year-end 2025.
Cash and equivalents ~$60M as of Dec 31, 2024; secured up to €57.5M EIB debt, extending runway into Q2 2026.
Phase 2 basket trial (resectable melanoma/SCCHN) enrollment completed at 95 patients; initial data expected H2 2025.
Phase 2 IOB-022 met primary endpoint ORR in SCCHN; promising PFS in SCCHN and NSCLC; longer-term data H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.